Skip to content
HowShorted

MYRIAD GENETICS INC short interest in 2025

In 2025, MYRIAD GENETICS INC's disclosed short interest ran from 5.29% of shares outstanding on 15 Jan 2025 to 10.34% on 31 Dec 2025, a change of +5.05 percentage points. The year's high was 10.34% on 31 Dec 2025 and its low 5.29% on 15 Jan 2025, averaging 7.85% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 10.44 days on 31 Dec 2025. Full history: MYRIAD GENETICS INC.

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for MYRIAD GENETICS INC in 2025

2025 in figures

Start of year
5.29% (15 Jan 2025)
End of year
10.34% (31 Dec 2025)
Change
+5.05 pp
High
10.34% (31 Dec 2025)
Low
5.29% (15 Jan 2025)
Average
7.85%
Highest days to cover
10.44 (31 Dec 2025)
SEC filings marked
9

Every report in 2025

MYRIAD GENETICS INC short interest in 2025
SettlementShort interestDays to coverFilings since previous
15 Jan 20255.29%5.30results (8-K)
31 Jan 20255.34%3.94
14 Feb 20255.96%5.37
28 Feb 20255.39%3.23results (8-K), 10-K filed
14 Mar 20255.59%4.81
31 Mar 20255.89%6.68
15 Apr 20255.67%4.81
30 Apr 20256.14%2.59
15 May 20258.59%1.86results (8-K), 10-Q filed
30 May 20259.52%4.08
13 Jun 20259.09%3.83
30 Jun 20258.12%4.68
15 Jul 20258.20%6.74
31 Jul 20259.22%5.92
15 Aug 202510.07%2.87results (8-K), 10-Q filed
29 Aug 20259.66%7.20
15 Sep 20259.13%5.48
30 Sep 20258.37%4.87
15 Oct 20258.34%7.97
31 Oct 20257.69%8.40
14 Nov 20258.25%5.44results (8-K), 10-Q filed
28 Nov 20259.19%6.61
15 Dec 20259.26%9.58
31 Dec 202510.34%10.44

See also: MYRIAD GENETICS INC's full history · most shorted US stocks of 2025 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.